Suzanne E. Wardell, Ph.D.
Affiliations: | 2004 | University of Colorado Anschutz Medical Campus, Denver, Aurora, CO |
Area:
Molecular BiologyGoogle:
"Suzanne Wardell"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Dean P. Edwards | grad student | 2004 | University of Colorado, Denver | |
| (Jun dimerization protein 2 coactivates transactivation by the progesterone receptor N-domain by a novel allosteric mechanism.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Chakraborty B, Chakraborty P, Brown MC, et al. (2024) Estrogens increase cancer cell efferocytosis to establish an immunosuppressive tumor microenvironment. Biorxiv : the Preprint Server For Biology |
| Killarney ST, Mesa G, Washart R, et al. (2024) PKN2 is a dependency of the mesenchymal-like cancer cell state. Cancer Discovery |
| Artham S, Juras PK, Goyal A, et al. (2024) Estrogen signaling suppresses tumor-associated tissue eosinophilia to promote breast tumor growth. Science Advances. 10: eadp2442 |
| Safi R, Wardell SE, Watkinson P, et al. (2024) Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells. Nature Communications. 15: 7675 |
| Price MJ, Nguyen AD, Haines C, et al. (2024) UDP-6-glucose dehydrogenase in hormonally responsive breast cancers. Biorxiv : the Preprint Server For Biology |
| Haines CN, Wardell SE, McDonnell DP. (2021) Current and emerging estrogen receptor-targeted therapies for the treatment of breast cancer. Essays in Biochemistry |
| McDonnell DP, Wardell SE, Chang CY, et al. (2021) Next-Generation Endocrine Therapies for Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2003565 |
| Andreano KJ, Baker JG, Park S, et al. (2020) The dysregulated pharmacology of clinically relevant ESR1 mutants is normalized by ligand-activated WT receptor. Molecular Cancer Therapeutics |
| Andreano KJ, Wardell SE, Baker JG, et al. (2020) G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer. Breast Cancer Research and Treatment |
| Wardell SE, Yllanes AP, Chao CA, et al. (2019) Correction to: Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy. Breast Cancer Research and Treatment |